Analytics, not advice. Rankings and scores describe past performance and are not recommendations.
32slipping
Latest NAV
₹170.1273
as of 07 Aug 2026
AUM
—
Expense ratio
—
Inception
14 May 2026
FundScore
32/100slipping
Rank #206 of 322 · top 68%
A daily percentile of this fund’s past performance within its SEBI category — analytics, not advice, and not a prediction or recommendation.
Trailing returns
Annualised returns to the latest NAV. Refreshed nightly.
1M
3.59%
3M
8.57%
6M
18.35%
1Y
16.95%
3Y CAGR
19.83%
5Y CAGR
13.53%
Since incep.
14.52%
NAV history
Zoom and pan · ranges from 1M to since-inception.
Rolling returns
Every 30-day step. The true distribution, not cherry-picked.
Rank history
Percentile within category over the last 2 years.
FundScore components
Pro-only breakdown of consistency, recency, and volatility scores.
Upgrade to Pro to see the raw drivers behind this scheme's FundScore label.
Pro
Market-cap distribution
Large / mid / small / micro-cap split of this fund's equity holdings, from its latest look-through portfolio. Shown as a share of classified equity.
Large cap64.4%
Mid cap33.7%
Small cap1.9%
Stock holdings
Latest portfolio disclosure for this scheme. Snapshot as of 30 Apr 2026.
Sun Pharmaceutical Industries Limited
equity
19.04%
Divi's Laboratories Limited
equity
8.21%
Dr. Reddy's Laboratories Limited
equity
8.02%
Apollo Hospitals Enterprise Limited
equity
7.81%
Max Healthcare Institute Limited
equity
7.35%
Cipla Limited
equity
7.33%
Lupin Limited
equity
5.56%
Fortis Healthcare Limited
equity
4.78%
Torrent Pharmaceuticals Limited
equity
4.35%
Laurus Labs Limited
equity
4.26%
Aurobindo Pharma Limited
equity
3.86%
Glenmark Pharmaceuticals Limited
equity
3.60%
Alkem Laboratories Limited
equity
3.14%
Biocon Limited
equity
2.55%
Mankind Pharma Limited
equity
2.53%
Zydus Lifesciences Limited
equity
2.22%
IPCA Laboratories Limited
equity
2.11%
Abbott India Limited
equity
1.31%
Piramal Pharma Limited
equity
1.00%
Syngene International Limited
equity
0.88%